1. Home
  2. EVTC vs MESO Comparison

EVTC vs MESO Comparison

Compare EVTC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVTC
  • MESO
  • Stock Information
  • Founded
  • EVTC 1988
  • MESO 2004
  • Country
  • EVTC United States
  • MESO Australia
  • Employees
  • EVTC N/A
  • MESO N/A
  • Industry
  • EVTC EDP Services
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • EVTC Technology
  • MESO Health Care
  • Exchange
  • EVTC Nasdaq
  • MESO Nasdaq
  • Market Cap
  • EVTC 2.0B
  • MESO 2.0B
  • IPO Year
  • EVTC 2013
  • MESO N/A
  • Fundamental
  • Price
  • EVTC $35.56
  • MESO $13.45
  • Analyst Decision
  • EVTC Hold
  • MESO Buy
  • Analyst Count
  • EVTC 3
  • MESO 4
  • Target Price
  • EVTC $35.67
  • MESO $18.00
  • AVG Volume (30 Days)
  • EVTC 418.1K
  • MESO 339.4K
  • Earning Date
  • EVTC 04-30-2025
  • MESO 02-26-2025
  • Dividend Yield
  • EVTC 0.56%
  • MESO N/A
  • EPS Growth
  • EVTC 42.98
  • MESO N/A
  • EPS
  • EVTC 1.73
  • MESO N/A
  • Revenue
  • EVTC $845,486,000.00
  • MESO $5,670,000.00
  • Revenue This Year
  • EVTC $7.85
  • MESO $228.57
  • Revenue Next Year
  • EVTC $5.39
  • MESO $356.77
  • P/E Ratio
  • EVTC $20.82
  • MESO N/A
  • Revenue Growth
  • EVTC 21.70
  • MESO N/A
  • 52 Week Low
  • EVTC $28.76
  • MESO $2.05
  • 52 Week High
  • EVTC $40.67
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • EVTC 52.62
  • MESO 32.97
  • Support Level
  • EVTC $36.79
  • MESO $12.40
  • Resistance Level
  • EVTC $38.32
  • MESO $15.15
  • Average True Range (ATR)
  • EVTC 0.96
  • MESO 0.93
  • MACD
  • EVTC 0.02
  • MESO -0.32
  • Stochastic Oscillator
  • EVTC 56.13
  • MESO 21.52

About EVTC Evertec Inc.

Evertec Inc is a transaction processing business in Latin America and the Caribbean. Its business segments are Merchant Acquiring, Payment Services - Puerto Rico & Caribbean, Latin America Payments and Solutions, and Business Solutions which derive maximum revenue. The company serves a diversified customer base of financial institutions, merchants, corporations, and government agencies with mission-critical technology solutions that enable them to issue, process, and accept transactions securely.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: